Correlation Of The Ratio Of Igm/Igg Concentration To Days After Symptom Onset (Igm/T Or Igg/T) With Disease Severity And Outcome In Non-Critical Covid-19 Patients

Yan Rong,Fei Wang,Xiaoli Li,Xinhua Liang,Yang Zhou,Dandan Zhang,Jing Liu,Huadong Zeng,Jing Wang,Yi Shi
2021-01-01
American journal of translational research
Abstract:Background: Correlation of SARS-CoV-2 serum antibodies with COVID-19 development and outcome has not been fully studied. Due to the time dynamic of antibodies, the antibody concentration of the same patient varies greatly at different times during the course of the disease. Therefore, our study used IgM/T or IgG/T (the ratio of serum antibody concentration to days after symptom onset) to reflect the patient's humoral immune status, and analyzed their correlation with COVID-19 development and outcome. Methods: Clinical data of 50 non-critical COVID-19 patients were retrospectively analyzed. Time-resolved fluorescence immunochromatography was used to quantitatively detect SARS-CoV-2 IgM and IgG. Correlation analysis was performed. Results: IgM antibody was positive on day 5 of symptom onset, increased within 2 weeks, and then gradually decreased. However, IgG antibody was positive on week 2 of symptom onset and continued to increase since. Additionally, IgM/T, but not IgG/T of recovery period (Spearman rho=0.17; P=0.283), was negatively correlated with disease course in 2 weeks of symptom onset (Spearman rho=-0.860; P=0.000). IgG/T of recovery period was positively correlated with clinical classification (Spearman rho=0.432; P=0.004), number of involved lung lobes (Spearman rho=0.343; P=0.026), and lung lesions (Spearman rho=0.472; P=0.002). Conclusions: Within 2 weeks of symptom onset, higher IgM/T indicates faster recovery and shorter disease course. In recovery period, higher IgG/T suggests more serious disease. IgM/T or IgG/T may predict disease severity and outcome in non-critical COVID-19 patients.
What problem does this paper attempt to address?